Cytonus Therapeutics to Present Preclinical Data for Systemically Delivered Oncolytic Virus Program for Treating Metastatic Cancers at AACR 2022

SAN DIEGO, Calif.–(BUSINESS WIRE)–Cytonus Therapeutics Inc. (Cytonus), a biotechnology company developing therapeutic products for targeted delivery in vivo, announces that their CSO, Dr. Richard Klemke Ph.D., will present the preclinical progress made on Cytonus’ lead Cargocyte product candidates at the annual AACR meeting in New Orleans. Cargocytes loaded with an Oncolytic Virus (CA-OV-VSV) are engineered to actively home, migrate, and penetrate into tumor micrometastatic foci, hours after
Click here to view original post